Of 235 Mycobacterium tuberculosis isolates from patients who had not received tuberculosis treatment in the Irkutsk oblast and the Sakha Republic (Yakutia), eastern Siberia, 61 (26%) were multidrug resistant. A novel strain, S 256, clustered among these isolates and carried eis-related kanamycin resistance, indicating a need for locally informed diagnosis and treatment strategies.
I
n 2010, tuberculosis (TB) prevalence in the Russian Federation was 136 cases per 100,000 population; the estimated proportion of multidrug resistance, defined as resistance to isoniazid and rifampin in the absence of prior treatment (primary MDR TB), was 18% (1) . However, at the subnational level, primary MDR TB might be highly variable; in oblasts or republics with continuous surveillance data, drug resistance varies from 5.4% to 28.3% (2) . These data are predominantly from the western half of the country and do not include eastern Siberia.
In 2009, in the Irkutsk oblast in eastern Siberia, TB prevalence was 373 cases per 100,000 population and HIV prevalence was among the highest in the Russian Federation (3, 4) . In contrast, in the sparsely populated neighboring Sakha Republic (Yakutia), TB prevalence was lower (188 cases/100,000 population) and HIV was thought to be scarce (4) . Molecular typing has found that more than half of the Mycobacterium tuberculosis isolates from the Russian Federation are the Beijing genotype, a pandemic lineage associated with MDR phenotype and characteristic drug-resistance mutations; prevalence of this genotype in Irkutsk is high (5, 6) . However, such investigation has not been performed in Yakutia. Given the distinct sociocultural patterns between Irkutsk and Yakutia, we hypothesized that the molecular epidemiology and drug-resistance patterns of M. tuberculosis from patients with primary MDR TB would be regionally distinct.
The Study
From November 2008 through May 2010, M. tuberculosis isolates were cultured during routine care of adults >18 years of age with primary TB and no history of treatment. The patients were from 2 regional referral centers, the Irkutsk Regional TB-Prevention Dispensary and the Research Practice Center for Phthisiatry (Yakutia); the study was approved by the institutional review boards at the University of Virginia and Irkutsk State Medical University.
Initial pretreatment isolates were grown on Lowenstein-Jensen agar slants and identified to species in accordance with World Health Organization recommendations. Drug susceptibility was tested by absolute concentration method on agar slants; drugs tested were rifampin (critical concentration 40 µg/mL), isoniazid (1 µg/mL and 10 µg/mL), ethambutol (2 µg/mL), streptomycin (10 µg/ mL), ethionamide (30 µg/mL), and kanamycin (30 µg/ mL). Susceptibility to a fluoroquinolone and pyrazinamide was not routinely tested. DNA extraction was performed on all isolates, followed by 12-loci mycobacterial interspersed repetitive unit-variable number tandem repeat (MIRU-VNTR) analysis (7) and further lineage definition by region of difference deletions, or for Ural strains as described (5). Phylogenetic tree construction was based on the MIRUVNTRplus database (8) , and VNTR international type numbers were confirmed on the SITVIT database (9) . DNA from MDR isolates was amplified and sequenced for the known drug-resistance determining regions katG, inhA, rpoB, embB, gyrA, rrs, and eis by using methods described by the Centers for Disease Control and Prevention (10 Among isolates from patients with primary MDR TB, 51 (84%) were available for DNA sequencing: 27 from Yakutia and 24 from Irkutsk (Table 2 ; an expanded version of this table is available at wwwnc.cdc.gov/EID/ article/19/10-1108-T2.htm). Among isoniazid-resistant isolates, the mutation in codon 315 of katG was present in 91%. Among rifampin-resistant isolates, mutations in the resistance-determining region of rpoB (codons 511-533) were present in only 79%. The pncA mutation was common across genotypes from both sites, occurring in 62% of isolates amplified. Notably, both isolates with mutation in eis from Yakutia occurred in MDR strains with the S 256 genotype and without rrs mutation.
Conclusions
In eastern Siberia, >25% of primary TB was MDR, equivalent to the highest proportion reported from the Russian Federation (2). However, regionally specific genotypic patterns and resistance mutations were identified. As expected, in Irkutsk primary MDR TB was driven by strains of Beijing lineage (5, 6 ). Yet in the more geographically isolated population of Yakutia, a strain previously unidentified in the Russian Federation, S 256, had a MIRU profile recently found among Canadian Aboriginal populations (11). In Yakutia, S 256 was highly drug resistant and was the most common genotype among patients with primary MDR TB.
Although rpoB mutations were found in only 79% of rifampin-resistant isolates, these findings are consistent with those in a recent report from Novosibirsk oblast, which similarly included non-Beijing and S-family strains and found a sensitivity of only 63% for the rpoB mutation (12) . Lack of phenotypic correlation can result from alternate mechanisms of resistance or imperfect conventional susceptibilities in Lowenstein-Jensen medium or from use of old drug stock. Such discrepancy necessitates urgent clarification because substitution of conventional susceptibility testing with molecular probe-based methods such as GeneXpert MTB/RIF (Cepheid, CA, USA) has been strongly advocated but would lead to dramatically different results and treatment regimens (13) . Of note, isolates of the S 256 strain accounted for a proportion of the cases in which mutation in the promoter region of eis was associated with kanamycin resistance, but rrs was wild type. Commercial assays have focused on the rrs locus, which has greater sensitivity for amikacin, as the sole target for the class of injectable agents (14) , yet in Eastern Siberia, the injectable agent available is kanamycin. Furthermore, we found a range of reported and unreported mutations across the entire pncA gene; most were point mutations resulting in amino acid substitution, but some strains had mutations that resulted in deletion or frameshift. Phenotypic methods and assays of functional pyrazinamidase activity should be performed in this region because results might have major implications for novel MDR TB drugs that work best with pyrazinamide (15) .
Study limitations include selection bias of isolates from passive surveillance. We were unable to obtain detailed clinical information about all patients with primary TB, thus preventing adequate comparison of nongenotypic risk factors for MDR TB or establishment of definitive (4) 2 (100) Ser531Tryp/Val456Gly 1 (2) 1 (100) Gln513Lys 2 (4) 2 (100) Leu533Pro 1 (2) 1 (100) His516Tyr 1 (2) 1 ( 
